BHC:NYE-Bausch Health Companies Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NYE

Last Closing Price

USD 28.60

Change

0.00 (0.00)%

Market Cap

USD 10.41B

Volume

1.91M

Avg Analyst Target

USD 38.67 (+35.20%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ZTS Zoetis Inc

N/A

USD96.66B 54.88 34.59
TAK Takeda Pharmaceutical Company ..

N/A

USD53.28B 15.52 0.08
CTLT Catalent, Inc

N/A

USD19.80B 39.37 21.03
ELAN Elanco Animal Health Incorpora..

N/A

USD16.99B 144.89 147.94
RDY Dr. Reddy's Laboratories Limit..

N/A

USD12.11B 52.46 0.30
TEVA Teva Pharmaceutical Industries..

N/A

USD9.80B 872.00 16.02
PRGO Perrigo Company plc

N/A

USD6.19B 24.33 28.76
EBS Emergent BioSolutions Inc

N/A

USD3.45B 9.05 5.70
TARO Taro Pharmaceutical Industries..

N/A

USD2.67B 10.60 10.99
AMRX Amneal Pharmaceuticals, Inc

N/A

USD0.72B 8.92 9.35

ETFs Containing BHC

Symbol Name Weight Mer Price(Change) Market Cap
BSJL Invesco BulletShares 2021.. 0.00 % 0.42 %

N/A

USD0.63B
SHYL Xtrackers Short Duration .. 0.00 % 0.20 %

N/A

USD0.07B
SYBK:F SSgA SPDR ETFs Europe I p.. 0.00 % 0.40 %

N/A

USD0.17B
SYBJ:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.40 %

N/A

USD0.92B
SJNK:LSE SSgA SPDR ETFs Europe I p.. 0.00 % 0.40 %

N/A

USD0.17B
JNKS:LSE SSgA SPDR ETFs Europe I p.. 0.00 % 0.40 %

N/A

USD0.17B
PHYL PGIM Active High Yield Bo.. 0.00 % 0.53 %

N/A

USD0.07B
HYGV FlexShares Trust - FlexSh.. 0.00 % 0.37 %

N/A

USD0.28B
GHYB Goldman Sachs Access High.. 0.00 % 0.34 %

N/A

USD0.20B
CJNK SPDR ICE BofAML Broad Hig.. 0.00 % 0.15 %

N/A

USD0.07B
BSJP Invesco BulletShares 2025.. 0.00 % 0.42 %

N/A

USD0.27B
HYLB Xtrackers USD High Yield .. 0.00 % 0.15 %

N/A

USD6.88B
SJB ProShares Trust - ProShar.. 0.00 % 0.95 %

N/A

USD0.05B
RFUN ALPS ETF Trust - Riverfro.. 0.00 % 0.55 %

N/A

USD0.01B
HYLS First Trust Tactical High.. 0.00 % 1.01 %

N/A

USD2.36B
HYG iShares Trust - iShares i.. 0.00 % 0.48 %

N/A

USD20.37B
SYBK:XETRA SSgA SPDR ETFs Europe I p.. 0.00 % 0.40 %

N/A

USD0.17B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.50% 82% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.50% 82% B- 87% B+
Trailing 12 Months  
Capital Gain 67.74% 88% B+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.74% 88% B+ 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.79% 50% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.79% 50% F 39% F
Risk Return Profile  
Volatility (Standard Deviation) 34.19% 56% F 31% F
Risk Adjusted Return 14.01% 56% F 24% F
Market Capitalization 10.41B 71% C- 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.11 93% A 91% A-
Price/Book Ratio 18.78 12% F 5% F
Price / Cash Flow Ratio 9.37 35% F 46% F
EV/EBITDA 17.47 46% F 37% F
Management Effectiveness  
Return on Equity -39,003.83% 6% F 5% F
Return on Invested Capital 6.57% 53% F 62% D-
Return on Assets 2.88% 65% D 58% F
Debt to Equity Ratio 4,471.96% 7% F 0% N/A
Technical Ratios  
Short Ratio 9.24 12% F 4% F
Short Percent 5.96% 35% F 36% F
Beta 1.69 24% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector